| Literature DB >> 35203945 |
Misun Oh1, Minwoo Lee1.
Abstract
Prominent cortical vessels on susceptibility-weighted imaging (PCV-SWI) correlate with poor leptomeningeal collaterals. However, little is known about PCV-SWI in recanalization therapy-treated patients with anterior circulation large vessel occlusions (LVO). We investigated PCV-SWI-based assessment of leptomeningeal collaterals and outcome predictions in 100 such patients in an observational study. We assessed PCV-SWI using the Alberta Stroke Program Early CT Score and evaluated leptomeningeal collaterals on multiphase CT angiography (mCTA). Predictive abilities were analyzed using multivariable logistic regression and area of receiver operating curves (AUCs). The extent of PCV-SWI correlated with leptomeningeal collaterals on mCTA (Spearman test, r = 0.77; p < 0.001); their presence was associated with worse functional outcomes and a lower successful recanalization rate (adjusted odds ratios = 0.24 and 0.23, 95% CIs = 0.08-0.65 and 0.08-0.65, respectively). The presence of PCV-SWI predicted outcomes better than good collaterals on mCTA did (C-statistic = 0.84 vs. 0.80; 3-month modified Rankin Scale (mRS) 0-2 = 0.75 vs. 0.67 for successful recanalization). Comparison of AUCs showed that they had similar abilities for predicting outcomes (p = 0.68 for 3-month mRS 0-2; p = 0.23 for successful recanalization). These results suggest that PCV-SWI is a useful feature for assessing leptomeningeal collaterals in acute ischemic stroke patients with anterior circulation LVO and predicting outcomes after recanalization therapy.Entities:
Keywords: SWI; leptomeningeal collaterals; outcomes; prominent cortical vessel; recanalization therapy; stroke
Year: 2022 PMID: 35203945 PMCID: PMC8869791 DOI: 10.3390/brainsci12020184
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1PCV–SWI (A), CC–mCTA (B).
Patient characteristics, treatments, and outcomes according to the prominent cortical vessels on SWI.
| Patients, No. (%) | ||||
|---|---|---|---|---|
| Overall | PCV–SWI | No PCV–SWI | ||
| Demographics and clinical characteristics | ||||
| Age, mean (SD), years | 70 (13) | 71.4 (13) | 68 (13) | 0.15 a |
| Male sex | 54 (54.0) | 34 (50.7) | 20 (60.6) | 0.35 b |
| Baseline NIHSS score, median (IQR) | 16 (12, 18) | 16 (13, 19) | 15 (11, 18) | 0.18 c |
| Baseline SBP, median (IQR), mmHg | 140 (130, 160) | 140 (130, 160) | 140 (129, 160) | 0.43 c |
| Baseline glucose concentration, median (IQR) mg/dL | 130 (113, 160) | 137 (113, 157) | 124 (110, 169) | 0.88 c |
| Pre-stroke mRS | 0.98 d | |||
| 0 | 90 (90.0) | 61 (91.0) | 29 (87.9) | |
| 1 | 8 (8.0) | 4 (6.0) | 4 (12.1) | |
| 2 | 2 (2.0) | 2 (3.0) | 0 | |
| TOAST classification | 0.35 d | |||
| Large artery atherosclerosis | 19 (19.) | 9 (13.4) | 10 (30.3) | |
| Cardioembolism | 63 (63.0) | 47 (70.1) | 16 (48.5) | |
| Other determined or undetermined | 18 (18.0) | 11 (16.4) | 7 (21.2) | |
| History of stroke | 20 (20.0) | 16 (23.9) | 4 (12.1) | 0.20 e |
| Hypertension | 70 (70.0) | 50 (74.6) | 20 (60.6) | 0.15 b |
| Diabetes mellitus | 24 (24.0) | 17 (25.4) | 7 (21.2) | 0.65 b |
| Dyslipidemia | 14 (14.0) | 9 (13.4) | 5 (15.2) | 0.82 b |
| Atrial fibrillation | 57 (57.0) | 42 (62.7) | 15 (45.5) | 0.10 b |
| Current smoker | 22 (22.0) | 11 (16.4) | 11 (33.3) | 0.06 b |
| Pre-stroke medication | ||||
| Antiplatelet or anticoagulants agents | 41 (41.0) | 29 (43.3) | 12 (36.4) | 0.51 b |
| Statin | 17 (17.0) | 11 (16.4) | 6 (17.2) | 0.82 b |
| Reperfusion therapy type | ||||
| IV thrombolysis | 15 (15.0) | 9 (13.4) | 6 (18.2) | 0.73 d |
| Endovascular treatment | 30 (30.0) | 21 (31.3) | 9 (27.3) | |
| Combined therapy | 55 (55.0) | 37 (55.2) | 18 (54.5) | |
| Site of occlusion | 0.45 d | |||
| Middle cerebral artery | ||||
| M1 | 59 (59.0) | 37 (55.2) | 22 (66.7) | |
| M2 | 4 (4.0) | 3 (4.5) | 1 (3.0) | |
| Internal carotid artery | 37 (37.0) | 27 (40.3) | 10 (30.3) | |
| ASPECTS–SWI, median (IQR) | 4 (2, 6) | 4 (3, 6) | 9 (8, 9) | <0.01 c |
| Collateral score–mCTA, median (IQR) | 3 (2, 4) | 3 (2, 4) | 4 (4, 4) | <0.01 c |
| Good collateral status (CC–mCTA, 4–5) | 44 (44.0) | 17 (25.4) | 27 (81.8) | <0.01 b |
| Outcomes | ||||
| Successful recanalization (eTICI 2b-3) | 62 (62.0) | 36 (53.7) | 26 (78.8) | 0.02 b |
| Any intracerebral hemorrhage | 27 (27.0) | 19 (28.4) | 8 (24.2) | 0.66 b |
| 3-month mRS score | <0.01 b | |||
| 0–2 | 36 (36.0) | 17 (25.4) | 19 (57.6) | |
| 3–6 | 64 (64.0) | 50 (74.6) | 14 (42.4) | |
Abbreviations: PCV–SWI, prominent cortical vessel-susceptibility weighted image; SD, standard deviation; IQR, interquartile range; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; CE, cardioembolism; OE, other etiology; mCTA, multiphase CTA; ASPECTS, Alberta Stroke Program Early CT Score; eTICI, expanded Thrombolysis in Cerebral Infarction; mRS, modified Rankin Scale. a p-value by student’s t test, b p-value by chi-square test, c p-value by Mann–Whitney U test, d p-value by Cochran–Mantel–Haenszel shift test, e p-value by Fisher’s exact test.
Factors associated with good functional outcome at 3 months using logistic regression analyses.
| Unadjusted OR | Adjusted OR | |||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Age | 0.96 (0.93, 0.99) | 0.02 | 0.98 (0.93, 1.03) | 0.41 |
| Sex (male) | 1.88 (0.81, 4.36) | 0.14 | 0.86 (0.28, 2.64) | 0.79 |
| Baseline NIHSS score | 0.88 (0.81, 0.96) | 0.01 | 0.89 (0.80, 0.99) | 0.03 |
| Initial glucose, mg/dL | 0.99 (0.97, 0.99) | 0.03 | 0.98 (0.97, 0.99) | <0.01 |
| History of stroke | 0.25 (0.07, 0.93) | 0.04 | 0.25 (0.05, 1.36) | 0.11 |
| History of hypertension | 0.23 (0.01, 0.57) | <0.01 | 0.32 (0.10, 1.01) | 0.051 |
| Prior antithrombotic agent | 0.41 (0.17, 0.99) | 0.046 | 0.79 (0.25, 2.54) | 0.70 |
| Site of occlusion | 0.33 | |||
| M2 (reference) | - | |||
| M1 | 2.90 (0.29, 29.5) | 0.34 | ||
| Internal carotid artery | 0.58 (0.05, 6.57) | 0.66 | ||
| PCV–SWI | 0.25 (0.10, 0.61) | <0.01 | 0.24 (0.08, 0.70) | 0.01 |
Abbreviations: OR, odds ratio; CI, confidence interval; NIHSS, National Institute of Health Stroke Scale; PCV–SWI, prominent cortical vessel-susceptibility weighted image. Adjusted for age, sex, initial NIHSS score, glucose level at admission, history of hypertension, history of stroke, prior antiplatelet or anticoagulant agents, and prominent cortical vessels (PCV–SWI, 0–2).
Predictive ability of each imaging modality to discriminate outcomes using multivariable logistic regression analysis, receiver operating curve analysis, AIC, and BIC.
| Imaging Modality | Adjusted OR | AIC | BIC | |||
|---|---|---|---|---|---|---|
| Good functional outcome | ASPECT-SWI (0–10), increase per 1 score | 1.45 (1.16, 1.82) | <0.01 | 0.86 | 105 | 129 |
| PCV–SWI (≤7 versus >7) | 0.24 (0.08, 0.70) | 0.01 | 0.84 | 112 | 135 | |
| CC–mCTA (0–5), increase per 1 score | 2.04 (1.26, 3.30) | <0.01 | 0.85 | 108 | 132 | |
| Good CC–mCTA (≥4 versus <4) | 1.91 (0.71, 5.13) | 0.19 | 0.80 | 117 | 140 | |
| Successful recanalization | ASPECT-SWI (0–10), increase per 1 score | 1.23 (1.08, 1.51) | <0.01 | 0.69 | 132 | 145 |
| PCV–SWI (≤7 versus >7) | 0.23 (0.08, 0.65) | <0.01 | 0.75 | 124 | 137 | |
| CC–mCTA (0–5), increase per 1 score | 1.49 (1.04, 2.13) | 0.03 | 0.70 | 127 | 140 | |
| Good CC–mCTA (≥4 versus <4) | 1.65 (0.68, 3.98) | 0.27 | 0.67 | 131 | 144 | |
| Any intracerebral hemorrhage c | ASPECT-SWI (0–10), increase per 1 score | 0.91 (0.77, 1.07) | 0.27 | 0.62 | 124 | 137 |
| PCV–SWI (≤7 versus >7) | 1.33 (0.50, 3.55) | 0.57 | 0.61 | 125 | 138 | |
| CC–mCTA (0–5), increase per 1 score | 0.92 (0.64, 1.33) | 0.67 | 0.61 | 125 | 138 | |
| Good CC–mCTA (≥4 versus <4) | 0.69 (0.27, 1.76) | 0.44 | 0.62 | 124 | 137 |
Abbreviations: OR, odds ratio; CI, confidence interval; AIC, Akaike information criterion; BIC, Bayesian information criterion; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Scale; PCV–SWI, prominent cortical vessel-susceptibility weighted image; CC–mCTA, collateral circulation score–multiphase CT angiography. a Adjusted for age, sex, baseline NIHSS score, baseline glucose level, history of hypertension, history of stroke, prior antiplatelet or anticoagulant use, and each imaging modality, b Adjusted for age, sex, history of hypertension, and each imaging modality, c Adjusted for age, sex, baseline glucose level, and each imaging modality.
Figure 2The comparison of AUCs between PCV–SWI and good collaterals–mCTA. (A) for predicting functional outcomes at 3 months, (B) for predicting achievement of successful recanalization, and (C) for predicting any intracerebral hemorrhage.